First Trust Direct Indexing L.P. Purchases 2,571 Shares of DexCom, Inc. (NASDAQ:DXCM)

First Trust Direct Indexing L.P. lifted its position in DexCom, Inc. (NASDAQ:DXCM) by 25.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,491 shares of the medical device company’s stock after acquiring an additional 2,571 shares during the quarter. First Trust Direct Indexing L.P.’s holdings in DexCom were worth $1,733,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Advisors Asset Management Inc. lifted its stake in shares of DexCom by 10.8% during the 3rd quarter. Advisors Asset Management Inc. now owns 16,291 shares of the medical device company’s stock worth $1,520,000 after purchasing an additional 1,588 shares during the last quarter. Alps Advisors Inc. boosted its holdings in shares of DexCom by 6.3% in the 3rd quarter. Alps Advisors Inc. now owns 12,877 shares of the medical device company’s stock valued at $1,201,000 after buying an additional 763 shares in the last quarter. Lido Advisors LLC grew its position in shares of DexCom by 1,485.9% in the 3rd quarter. Lido Advisors LLC now owns 56,298 shares of the medical device company’s stock worth $5,253,000 after buying an additional 52,748 shares during the last quarter. Legacy Advisors LLC raised its stake in shares of DexCom by 14.9% during the 3rd quarter. Legacy Advisors LLC now owns 6,584 shares of the medical device company’s stock worth $614,000 after acquiring an additional 852 shares in the last quarter. Finally, Kingdon Capital Management L.L.C. bought a new position in shares of DexCom during the 3rd quarter worth approximately $4,889,000. 97.75% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. Royal Bank of Canada started coverage on shares of DexCom in a report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price target on the stock. Raymond James boosted their target price on DexCom from $151.00 to $160.00 and gave the stock a “strong-buy” rating in a research note on Friday, April 26th. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a research note on Monday, June 10th. Citigroup increased their price objective on shares of DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Finally, Canaccord Genuity Group boosted their target price on shares of DexCom from $144.00 to $145.00 and gave the stock a “buy” rating in a research report on Friday, April 26th. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $140.33.

DexCom Price Performance

NASDAQ:DXCM opened at $110.91 on Friday. The firm’s fifty day moving average is $121.24 and its two-hundred day moving average is $125.37. The firm has a market cap of $44.11 billion, a price-to-earnings ratio of 71.56, a PEG ratio of 2.71 and a beta of 1.16. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90. DexCom, Inc. has a one year low of $74.75 and a one year high of $142.00.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $921.00 million for the quarter, compared to the consensus estimate of $911.20 million. DexCom had a return on equity of 31.01% and a net margin of 16.82%. Research analysts expect that DexCom, Inc. will post 1.78 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Kevin R. Sayer sold 49,633 shares of the business’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $138.30, for a total value of $6,864,243.90. Following the completion of the transaction, the chief executive officer now directly owns 283,893 shares in the company, valued at approximately $39,262,401.90. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, CEO Kevin R. Sayer sold 49,633 shares of the firm’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $138.30, for a total transaction of $6,864,243.90. Following the sale, the chief executive officer now directly owns 283,893 shares in the company, valued at approximately $39,262,401.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Bridgette P. Heller sold 1,000 shares of the company’s stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $113.55, for a total value of $113,550.00. Following the completion of the transaction, the director now directly owns 25,349 shares of the company’s stock, valued at approximately $2,878,378.95. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 55,735 shares of company stock worth $7,619,347. Corporate insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.